<DOC>
	<DOCNO>NCT02507752</DOCNO>
	<brief_summary>This multicenter prospective observational study evaluate quality life participant rheumatoid arthritis ( RA ) initiate rituximab ( MabThera/Rituxan ) . Participants follow 6 month initiation treatment .</brief_summary>
	<brief_title>An Observational Quality Life Study Participants With Rheumatoid Arthritis Treated With Rituximab</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult participant gender 18 year old Diagnosis RA least 6 month accord criterion American College Rheumatology ( ACR ) 1987 RA classification Participants medically prescribe administered unique rituximab infusion least 3 day , accord approve label Ability meet program 's requirement voluntarily sign Informed Consent Term . Participants receive investigational medication within less equal ( &lt; = ) 1 year first dose currently indicate treatment Participants active infection Participants condition may interfere ability understand request data collection obey study 's requirement Functional Class IV define base ACR functionality criterion RA Participants want , reason , answer questionnaire .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>